LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

LLY

1,006.06

+1.27%↑

JNJ

209.91

+1.6%↑

ABBV

223.8

-0.55%↓

UNH

336.55

+2.68%↑

AZN

90.26

-1.28%↓

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Chiusa

40.01 2.04

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

38.4

Massimo

40.68

Metriche Chiave
By Trading Economics
Entrata	-7.4M -81M
EPS	-0.5
Margine di Profitto	-1,582.642
Dipendenti	205
EBITDA	-6.8M -79M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+10.06% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	4B 6.2B
Apertura precedente	37.97
Chiusura precedente	40.01

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 dic 2025, 23:58 UTC

Acquisizioni, Fusioni, Takeovers

Destination XL to Merge With Oaktree-Backed Fullbeauty Brands -- Update

11 dic 2025, 23:56 UTC

Utili

Costco Logs Higher Sales, Eyes Expansion to Fuel Membership Growth -- Update

11 dic 2025, 23:03 UTC

Acquisizioni, Fusioni, Takeovers

FTC Sues to Block Henkel's $725 Million Acquisition of Liquid Nails From PE Firm

11 dic 2025, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Scentre to Sell $456 Million Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dic 2025, 21:50 UTC

Utili

Costco Same-Store Sales, Membership Fees Rose in 1Q

11 dic 2025, 23:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

11 dic 2025, 23:44 UTC

Discorsi di Mercato

Nikkei May Rise After U.S. Stock Indexes Hit Record Highs -- Market Talk

11 dic 2025, 23:37 UTC

Discorsi di Mercato

Gold Steady, Underpinned by Dollar's Weakness -- Market Talk

11 dic 2025, 23:31 UTC

Utili

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dic 2025, 22:48 UTC

Acquisizioni, Fusioni, Takeovers

FTC Sues to Block Henkel's $725M Acquisition of Liquid Nails From PE Firm

11 dic 2025, 22:35 UTC

Utili

Costco Sold 4.5 Million Pies Ahead of Thanksgiving. Despite Earnings Beat, the Stock Fails to Gain Traction. -- Barrons.com

11 dic 2025, 22:30 UTC

Utili

Broadcom Beats Earnings. The Stock Wavers After Customer Updates. -- Barrons.com

11 dic 2025, 22:09 UTC

Acquisizioni, Fusioni, Takeovers

FTC Alleges Henkel Deal Would Combine Two Biggest Brands of Construction Adhesives Sold at Stores Like Home Depot, Leading to Higher Prices

11 dic 2025, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

FTC Sues to Block Henkel From Buying Loctite Competitor Liquid Nails

11 dic 2025, 22:05 UTC

Utili

Broadcom Beats Revenue and Profit Forecasts as AI Chip Sales Climb -- Update

11 dic 2025, 21:51 UTC

Acquisizioni, Fusioni, Takeovers

Scentre to Sell $456M Westfield Chermside Mall Stake to Dexus-Managed Fund

11 dic 2025, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

11 dic 2025, 21:39 UTC

Utili

Broadcom Beats Earnings. The Stock Rises. -- Barrons.com

11 dic 2025, 21:39 UTC

Utili

Broadcom Reports $18 Billion in Revenue as AI Chip Sales Climb -- WSJ

11 dic 2025, 21:38 UTC

Utili

Costco Tops Earnings Estimates but Stock Fails to Gain Traction -- Barrons.com

11 dic 2025, 21:37 UTC

Utili

These Stocks Moved the Most Today: Oracle, Nvidia, Broadcom, Planet Labs, Visa, Ciena, Gemini Space Station, and More -- Barrons.com

11 dic 2025, 21:37 UTC

Discorsi di Mercato

Broadcom Sees AI Revenue Doubling -- Market Talk

11 dic 2025, 21:34 UTC

Acquisizioni, Fusioni, Takeovers

Scentre Will Temporarily Invest A$50M in the New Dexus Fund

11 dic 2025, 21:29 UTC

Acquisizioni, Fusioni, Takeovers

Dexus Aiming for Long-Term Holding of A$50M in Fund

11 dic 2025, 21:28 UTC

Discorsi di Mercato

BLS Publishing Calendar Delays Now Pushing Economic Data Into February -- Market Talk

11 dic 2025, 21:28 UTC

Acquisizioni, Fusioni, Takeovers

Dexus Expects to Introduce Additional Third-Party Equity in FY26

11 dic 2025, 21:28 UTC

Acquisizioni, Fusioni, Takeovers

Dexus: Third Party Investors to Contribute Remainder

11 dic 2025, 21:27 UTC

Acquisizioni, Fusioni, Takeovers

Dexus to Put Initial A$170M into New Dexus Strategic Investment Trust

11 dic 2025, 21:26 UTC

Acquisizioni, Fusioni, Takeovers

Scentre: Dexus Wholesale Shopping Centre Fund Already Holds 25% Stake

11 dic 2025, 21:25 UTC

Acquisizioni, Fusioni, Takeovers

Scentre: Purchase Price Represents Book Value, 5% Value Cap Rate

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

10.06% in crescita

Previsioni per 12 mesi

Media 43.11 USD 10.06%

Alto 53 USD

Basso 30 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.